Microbiome-Guided Precision Medicine: Turning a Bacterial Driver of Colorectal Cancer into a Druggable Target
| Reference number | |
| Coordinator | QureTech OncoBiome AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2026 - April 2028 |
| Status | Ongoing |
| Venture | Research infrastructure - utilisation and collaboration |
| Call | Support to small and medium-sized companies for the use of life science infrastructure |
Purpose and goal
The project aims to identify and validate new low molecular weight compounds that can affect a bacteria-related mechanism relevant to colorectal cancer. Computational methods will be combined with pharmacological screening to identify promising molecules as starting points for further drug development.
Expected effects and result
The project is expected to deliver a selection of pharmacologically active compounds with diverse chemical structures and potential for further development. The results will improve understanding of the mechanism studied and support the selection of molecules for the next development phase. In the longer term, the work may contribute to new treatment options for colorectal cancer.
Planned approach and implementation
The project is carried out by QureTech OncoBiome together with Chemical Biology Consortium Sweden (CBCS). Relevant pharmacological assays and computational models will be developed and validated. This will be followed by screening, confirmation and prioritization of hit compounds. The project will conclude with an integrated assessment and recommendation for further development.